Umbilical cord mesenchymal stem cells for the treatment of
refractory chronic graft-versus-host
disease

doi:10.3969/j.issn.2095-4344.2039

Abstract

Abstract:

BACKGROUND: Chronic graft-versus-host disease is the most common complication after transplantation and glucocorticoid is a first-line drug. Glucocorticoid in combination with immunosuppressive therapy is not effective in half of the patients with hormone resistant chronic graft-versus-host disease. The low immunogenicity of umbilical cord mesenchymal stem cells provides the possibility for clinical treatment of graft-versus-host disease.

OBJECTIVE: To investigate the clinical efficacy and safety of umbilical cord-derived mesenchymal stem cells to treat refractory chronic graft-versus-host disease.

METHODS: Fifteen patients with refractory chronic graft-versus-host disease received mesenchymal stem cell infusion treatment based on immunosuppressive therapy. The therapeutic efficacy, infusion-related adverse reactions, and survival were analyzed. The ratio change of peripheral blood lymphocytes was determined by flow cytometry. This study was approved by Medical Ethics Committee, Third Affiliated Hospital of Sun Yat-sen University in China.

RESULTS AND CONCLUSION: There were 12 male and 3 female patients with a median age of 29 years (ranging from 17 to 52 years). Four patients obtained complete response, seven patients obtained partial response, 11 had overall response, and four patients had no response. After treatment by umbilical cord mesenchymal stem cells, the ratio of CD19⁺ cells in the peripheral blood was slightly, but not significantly lower, but CD19⁺CD27⁺ and CD3⁺ cell ratios were slightly, but not significantly higher than those before treatment. No patients had adverse reactions related to infusion of umbilical cord mesenchymal stem cells and no patients had primary disease recurrence and mesenchymal stem cell-related tumor. These findings suggest that umbilical cord-derived mesenchymal stem cell infusion is an effective and safe therapy for refractory chronic graft-versus-host disease.

Key words: umbilical cord mesenchymal stem cell, hematopoietic stem cell transplantation, chronic graft-versus-host disease, peripheral blood lymphocyte ratio

CLC Number:

Zhang Ling, Sun Yanling, Wang Xiaozhen, Long Bing , Liu Jiajun. Umbilical cord mesenchymal stem cells for the treatment of refractory chronic graft-versus-host disease[J]. Chinese Journal of Tissue Engineering Research, 2020, 24(13): 2034-2038.

Figures/Tables 4

References

[1] ARAI S, ARORA M, WANG T, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant.2015;21(2):266-274.
[2] HERRMANN R, STURM M, SHAW K, et al. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study. Int J Hematol. 2012;95(2):182-188.
[3] GHANNAM S, BOUFFI C, DJOUAD F, et al. Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther. 2010;1(1):2.
[4] LI J, LI D, JU X, et al. Umbilical cord-derived mesenchymal stem cells retain immunomodulatory and anti-oxidative activities after neural induction. Neural Regen Res. 2012;7(34):2663-2672.
[5] CAMPAGNOLI C, ROBERTS IA, KUMAR S, et al. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood. 2001;98(8):2396-2402.
[6] IGURA K, ZHANG X, TAKAHASHI K, et al. Isolation and characterization of mesenchymal progenitor cells from chorionic villi of human placenta. Cytotherapy. 2004;6(6):543-553.
[7] LEE SJ, KLEIN JP, BARRETT AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood.2002;100(2):406-414.
[8] TOGHRAIE F, RAZMKHAH M, GHOLIPOUR MA, et al. Scaffold-free adipose-derived stem cells (ASCs) improve experimentally induced osteoarthritis in rabbits. Arch Iran Med. 2012;15(8):495-499.
[9] 庞荣清,何洁,李福兵,等.一种简单的人脐带间充质干细胞分离培养方法[J].中华细胞与干细胞杂志(电子版),2011,1(2):30-33.
[10] LEE SJ, WOLFF D, KITKO C, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015;21(6):984-999.
[11] WEISS ML, ANDERSON C, MEDICETTY S, et al. Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells. 2008; 26(11):2865-2874.
[12] LE BLANC K, RASMUSSON I, SUNDBERG B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363(9419):1439-1441.
[13] 陈广华,杨婷,田竣,等.脐带间充质干细胞治疗糖皮质激素耐药的严重型急性移植物抗宿主病19例分析[J].中华血液学杂志, 2012, 33(4):303-306.
[14] ZHAO K, HUANG F, PENG YW, et al. Clinical observation of mesenchymal stem cell as salvage treatment for refractory acute graft-versus-host disease. Zhonghua Xue Ye Xue Za Zhi. 2013;34(2): 122-126.
[15] 陆英,张祥忠,刘相富,等.间充质干细胞输注对移植物抗宿主病中不同受损器官的治疗效果[J].中国组织工程研究,2014,18(23):3676-3681.
[16] WENG JY, DU X, GENG SX, et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant. 2010; 45(12):1732-1740.
[17] INTRONA M, LUCCHINI G, DANDER E, et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transplant. 2014; 20(3):375-381.
[18] 张乐施,刘启发,黄科.间充质干细胞治疗糖皮质激素耐药性慢性移植物抗宿主病临床疗效观察[J].中华内科杂志, 2009,48(7):542-546.
[19] 张玲,张祥忠,李晓青,等.脐带间充质干细胞治疗难治性慢性移植物抗宿主病的疗效观察[J]. 器官移植,2016,11(7):459-462.
[20] ERBEY F, ATAY D, AKCAY A, et al. Mesenchymal Stem Cell Treatment for Steroid Refractory Graft-versus-Host Disease in Children: A Pilot and First Study from Turkey. Stem Cells Int. 2016;2016:1641402.
[21] FRASER CJ, SCOTT BAKER K. The management and outcome of chronic graft-versus-host disease. Br J Haematol. 2007;138(2): 131-145.
[22] PARKER PM, OPENSHAW H, FORMAN SJ. Myositis associated with graft-versus-host disease. Curr Opin Rheumatol. 1997;9(6):513-519.
[23] SRINIVASAN M, FLYNN R, PRICE A, et al. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood. 2012;119(6):1570-1580.
[24] JURADO M, DE LA MATA C, RUIZ-GARCÍA A, et al. Adipose tissue-derived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease: A phase I/II study. Cytotherapy. 2017;19(8):927-936.
[25] PENG Y, CHEN X, LIU Q, et al. Alteration of naïve and memory B-cell subset in chronic graft-versus-host disease patients after treatment with mesenchymal stromal cells. Stem Cells Transl Med. 2014;3(9): 1023-1031.
[26] NORDLANDER A, MATTSSON J, RINGDÉN O, et al. Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2004;10(3): 195-203.
[27] KOH LP, CHEN CS, TAI BC, et al. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy. Biol Blood Marrow Transplant. 2007;13(7):790-805.
[28] VAN DER STRAATEN HM, FIJNHEER R, DEKKER AW, et al. Relationship between graft-versus-host disease and graft-versus- leukaemia in partial T cell-depleted bone marrow transplantation. Br J Haematol. 2001;114(1):31-35.
[29] KIM N, IM KI, LIM JY, et al. Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice. Ann Hematol. 2013;92(10):1295-1308.
[30] BARON F, LECHANTEUR C, WILLEMS E, et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant. 2010;16(6):838-847.
[31] KUZMINA LA, PETINATI NA, PAROVICHNIKOVA EN, et al. Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease-A Phase II Study. Stem Cells Int. 2012; 2012:968213.